# DOD Amyotrophic Lateral Sclerosis, Clinical Outcomes and Biomarkers Award

Source: https://welltoldgrants.com/grants/ht942524alsrpcoba-dod-amyotrophic-lateral-sclerosis-clinical-outcomes-and/  
Official notice: https://www.grants.gov/search-results-detail/353158

> Defense Health Agency Contracting Activity - DHACA offered grants to any type of organization. It expected to make about 5 awards worth $6.1 million in total. Applications closed on July 10, 2024.

| Field | Value |
|---|---|
| Opportunity number | HT942524ALSRPCOBA |
| Agency | Defense Health Agency Contracting Activity - DHACA |
| Status | Forecast |
| Deadline | July 10, 2024 |
| Award ceiling | not stated |
| Award floor | not stated |
| Expected awards | 5 |
| Total funding | $6.1 million |
| Cost sharing | not required |
| Assistance Listings | 12.420 |

## Who can apply

- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

## What the grant funds

The FY24 ALSRP Clinical Outcomes and Biomarkers Award (COBA) supports the development and/or validation of clinical outcomes and biomarkers to enrich clinical trials in Amyotrophic Lateral Sclerosis (ALS). Projects can be relevant to a specific therapy, a class of therapeutics, or to a specific ALS subtype (such as a particular genetic mutation) and do not have to broadly apply to all patients. Research may include, but is not limited to: Target engagement biomarkers. Objective pharmacodynamic biomarkers to measure the biological effect of an investigational therapeutic. Predictive/cohort-selective biomarkers that indicate whether a specific therapy will be effective in an individual patient or patient subgroup. Diagnostic, prognostic, or disease progression Validate clinician-, observer-, patient-reported and/or performance outcomes to better support clinical trial success metrics. Define ALS subtypes using patient-based resources to link biosamples and/or digital data elements to rigorous molecular and clinical data. Realize improved strategies that better measure disease progression for people living with ALS. Augment biospecimens, outcome, or digital health data to an on-going clinical trial. Correlate clinical-trial related data (e.g., biosample, imaging, digital health data) with clinical outcomes or responses to therapies. Use of existing well-characterized and highly curated clinical resources is encouraged. Examples of patient-based ALS resources include ongoing or completed clinical trial datasets, biorepositories of clinical specimens, registries (e.g., Centers for Disease Control and Prevention National ALS Registry and/or Biorepository; https://www.cdc.gov/als/Default.html), large omics datasets, patient-report outcomes, digital biomarker datasets, and databases of clinical data and/or metadata. Active-duty military and/or Veteran patient populations or resources should be considered. A list of suitable resources can be found on the ALSRP web page (https://cdmrp.health.mil/alsrp/resources/ALSRPresources). Other resources may be used, provided they have an adequate description of repository parameters and mechanisms for broad access.

## Questions people ask

### Is HT942524ALSRPCOBA still open?

No. It closed on July 10, 2024. A newer notice is open: HT942526BCRPCREA2, closes November 18, 2026 (11 days left).

### Who can apply for DOD Amyotrophic Lateral Sclerosis, Clinical Outcomes and Biomarkers Award?

Defense Health Agency Contracting Activity - DHACA accepted applications from any type of organization.

### What is the deadline for DOD Amyotrophic Lateral Sclerosis, Clinical Outcomes and Biomarkers Award?

Closed July 10, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### How much funding is available?

About $6.1 million in total across about 5 awards.

### Who has won Military Medical Research and Development grants before?

The largest recipients over five fiscal years were The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Univeristy of Texas M.D. Anderson Cancer Center, The Johns Hopkins University. The program made 5,470 awards worth $6.9 billion in that time.